Very recently, the results of a phase 1b clinical trial using another TSLP-targeting therapy reported that patients with asthma treated with Verekitug (a potent long-acting anti-TSLP receptor antibody that only requires a 6-month dosing) had decreased Feno levels and blood eosinophil counts 24 weeks after biologic cessation (reviewed in [137]). This evidence concerns the gene TSLP and asthma.